Seeking Alpha

Jazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of...

Jazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of patients treated with Erwinaze for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The trial, which was presented at the American Society of Hematology Annual Meeting and Exposition, includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the drug's known safety profile.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|